症状・状態

18 エビデンスに基づいたサプリメント研究のある健康状態

Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.

How We Grade Evidence

各症状ページでは、臨床エビデンスの強さに基づいてサプリメント成分をランク付けしています。各グレードの意味は以下の通りです：

Strong Evidence

Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.

Good Evidence

At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.

Some Evidence

Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.

Very Early Research

In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.

Ulcerative Colitis (UC)

~0.3% in Western countries; peak onset 15-30 years

Bloody diarrhea Rectal bleeding Abdominal pain (left-sided) +4

Gastroesophageal Reflux Disease (GERD)

20-30% in Western populations; 5-10% in Asia

Heartburn Regurgitation Dysphagia +5

Chronic Constipation

15-20% of adults globally; increases with age; more common in women

Infrequent bowel movements Hard/lumpy stools Straining +3

Acute Diarrhea

1.7 billion cases of childhood diarrhea globally per year; 525,000 deaths

Loose/watery stools Abdominal cramps Nausea +4

Antibiotic-Associated Diarrhea (AAD)

5-39% of antibiotic users; varies by antibiotic class

Loose/watery stools Abdominal cramping Low-grade fever +1

Clostridioides difficile Infection (CDI)

500,000 infections/year in the US; 29,000 deaths

Watery diarrhea (>=3/day) Abdominal pain Fever +2

Functional Dyspepsia

10-20% of the general population

Postprandial fullness Early satiation Epigastric pain +3

Increased Intestinal Permeability (Leaky Gut)

Prevalence uncertain; measurable by lactulose/mannitol ratio test. Common in IBD, celiac disease, alcoholism

Often subclinical Fatigue Food sensitivities +4

Lactose Intolerance

65-70% of global population (varies widely by ethnicity: 5% Northern European to 90% East Asian)

Bloating Gas Abdominal cramps +2

Traveler's Diarrhea

30-70% of travelers to high-risk areas depending on destination

Watery diarrhea Abdominal cramps Nausea +4

Peptic Ulcer Disease

5-10% lifetime prevalence; declining due to H. pylori treatment

Epigastric pain (burning, gnawing) Pain worse with empty stomach (duodenal) or after meals (gastric) Nausea +2

Bloating and Intestinal Gas

15-30% of general population report regular bloating; more common in IBS patients (>75%)

Abdominal fullness/distension Excessive flatulence Belching +3

Irritable Bowel Syndrome (IBS)

10-15% of global population; more common in women (2:1 ratio)

Abdominal pain/cramping Bloating Gas +5

Crohn's Disease

~0.3% in Western countries; peak onset 15-35 years

Abdominal pain (right lower quadrant) Chronic diarrhea Weight loss +4

Small Intestinal Bacterial Overgrowth (SIBO)

Estimated 6-15% in healthy population; up to 80% in IBS patients

Bloating Gas Abdominal pain +6

Helicobacter pylori Infection

~50% of global population infected; higher in developing countries

Often asymptomatic Epigastric pain Nausea +3

Gut Dysbiosis

Prevalence not precisely defined; associated with Western diet, antibiotic use, and numerous chronic diseases

Bloating Gas Irregular bowel habits +5

Inflammatory Bowel Disease (IBD) — General

~0.5% in Western countries; rising incidence in Asia and South America

Chronic diarrhea Abdominal pain Rectal bleeding +3

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。